l e t t e r s
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10 −8 to P = 2.7 × 10 −24 ). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ~25% of the familial risk in this disease, have now been identified.
Genome-wide association studies (GWAS) provide a powerful approach to identify common disease alleles. We previously conducted a GWAS based on genotyping of 541,129 SNPs in 1,854 clinically detected PrCa cases and 1,894 controls (stage 1) 1 . In a second stage, we genotyped 43,671 SNPs showing evidence for association in stage 1 in 3,650 PrCa cases and 3,940 controls (stage 2). These studies, together with further follow up through the PRACTICAL consortium, identified 16 PrCa susceptibility loci [1] [2] [3] . Taken together with loci identified through other GWAS, more than 30 PrCa susceptibility loci have been reported 4 , and these account for approximately 23% of the familial risk of the disease.
Because the risks associated with common susceptibility alleles are modest (with per-allele odds ratios (OR) ranging from 1.10 to 1.25), it is likely that other PrCa predisposition loci have been missed by previous studies and that such loci should be detectable by studies with larger sample sizes 5 . We therefore conducted a more extensive follow up of SNPs showing evidence of association in our GWAS. We first used imputation, utilizing the HapMap phase II CEU data as a reference, to estimate genotypes in our stage 1 and 2 data at ~2.6 million SNPs. To improve power, we then combined these data with imputed data from the Cancer Genetic Markers of Susceptibility (CGEMS) PrCa study, a GWAS of 1,117 PrCa cases and 1,105 controls, using a stratified 1 degree of freedom (df) P trend (Online Methods).
We used these combined results to select SNPs for a stage 3 analysis. We selected 1,263 SNPs based on their ranked P values together with 178 additional SNPs selected for fine mapping of three regions, of known susceptibility loci or from candidate gene studies (Online Methods). We genotyped these SNPs using an Illumina GoldenGate assay in 4,999 PrCa cases and 4,939 controls from the UK and Australia (see Online Methods and Supplementary Note). After quality control exclusions (Online Methods), we utilized data from 1,347 SNPs in 4,574 PrCa cases and 4,164 controls (Supplementary Fig. 1) . We compared the genotype frequencies in cases and controls using a 1-df Cochran-Armitage trend test stratified by study.
After exclusion of SNPs in previously known susceptibility regions, there was a clear excess of nominally significant associations in stage 3, with 11 SNPs significant at P < 0.001 (in seven regions on chromosomes 2, 5, 6 and 12) compared with the 1.1 that would be expected by chance. We then combined the data from stage 3 with those from the previous stages and with the CGEMS data. In the combined dataset, we identified 16 SNPs from ten regions in which the highest ranking SNP reached a significance of P < 10 −7 in the combined analysis or P < 10 −3 in stage 3. Multiple logistic regression analysis indicated that a single SNP was sufficient to explain the association signal at each region, in that no further SNPs were significantly associated with risk after adjustment for the most strongly associated SNP.
We then subjected these ten SNPs to further replication analysis (stage 4) in an international study involving 26,055 cases and 25,256 controls from 30 studies participating in the PRACTICAL Consortium ( Supplementary Fig. 1 and Supplementary Note). Nine SNPs showed evidence of replication in stage 4 (P ≤ 0.007), each in the same direction as in stages 1-3, with a significance of P = 4.0 × 10 −8 to P = 2.7 × 10 −24 in a combined analysis across all stages ( Table 1 , Fig. 1 and Supplementary Fig. 1 ). rs37181 on 5q22 showed no evidence of association in stage 4 and did not reach the genome-wide significance threshold in an overall combined analysis (P = 0.17 in stage 4 and P = 5.3 × 10 −5 overall). Of the nine loci reaching genomewide significance, rs7584330 is in the same region as a locus recently reported in a parallel GWAS of PrCa 6 . The second stage of that study also included data from stages 1 and 2 of our GWAS. The associated SNP in that study, rs2292884, is in linkage disequilibrium (LD) with l e t t e r s the SNP reported here, rs7584330 (r 2 = 0.59), and is likely to reflect the same signal, although rs7584330 showed a stronger association in our GWAS (Supplementary Fig. 2a) .
rs2242652 on 5p15 lies in intron 3 of TERT (encoding telomerase reverse transcriptase) (Fig. 2a) . SNPs in this region have been associated with multiple cancers, including basal cell carcinoma, lung cancer, bladder cancer, glioma and testicular cancer 7 . Some evidence for an association with PrCa risk has also previously been reported for rs401681 and rs2736098 in this region (P = 3.6 × 10 −4 and P = 1.3 × 10 −4 ) 7 . In contrast, we found much stronger evidence of an association with rs2242652 in the same region. The associated SNP newly identified in this GWAS, rs2242652, is weakly correlated with the previously l e t t e r s reported rs401681 (r 2 = 0.19) and showed a much stronger association with PrCa risk in our original GWAS (P = 9.8 × 10 −11 in stages 1 and 3 and CGEMS compared to P = 0.001 for rs401681). Multiple logistic regression analysis indicated that rs2242652 was associated with PrCa risk after adjustment for rs401681 (P = 4.6 × 10 −9 and P = 0.07, respectively). In a stepwise logistic regression including both SNPs, rs2242652 alone remained in the model (P = 4.4 × 10 −11 ). rs2242652 is also modestly correlated with rs2736098 (r 2 = 0.10), although the latter SNP was not genotyped in any stage of our GWAS. Thus, rs2242652 may be more strongly correlated to the variant(s) causally related to PrCa risk than either rs401681 or rs2736098. This may also indicate that the variant(s) functionally related to PrCa risk in the TERT region differs from those for other cancers. The major role of telomerase is to catalyze the de novo addition of telomeric repeat sequences onto chromosome ends and thereby counterbalance telomere-dependent replicative aging. Several studies have reported an association between short telomeres and increased risk of cancer at several sites, although the cancerassociated SNPs in TERT have thus far not been associated with telomere length. All but one of the autosomal SNPs associated with PrCa risk show a pattern of association consistent with a log-additive model, as observed for most common cancer susceptibility alleles (Supplementary Table 1) . For rs2121875 at 5p12, the estimated OR in stage 4 for rare allele homozygotes is 1.14 (95% CI 1.07-1.21), which is greater than expected under a log-additive model (P = 0.02).
There was some evidence for a difference in the per-allele ORs among European, Asian and African-American populations for rs2121875 (P = 0.03 for heterogeneity in the OR by population; Supplementary Table 2) . However, the sample sizes for the Asian and African-American populations were too small to evaluate the associations in these populations reliably.
We were able to examine the associations between genotypes of the ten SNPs selected for replication in PRACTICAL and serum prostate-specific antigen (PSA) in 1,089 control samples from stage 3 of our scan and 1,540 controls from stage 4 (Supplementary Table 3 ). One SNP, rs2242652 (chromosome 5p15, TERT) showed an association with PSA level (P = 0.006) in the direction consistent with its association with PrCa risk.
Data on Gleason score were available for 19,959 PrCa European cases. There was some evidence of a higher per-allele OR for Gleason score ≥8 disease for one SNP, rs5919432 Odds ratio
Odds ratio
Odds ratio
Odds ratio l e t t e r s (Xq12; Supplementary Table 4 ). This general lack of association with aggressiveness is broadly consistent with the other susceptibility loci identified through GWAS. Four SNPs, however, showed evidence of a differential association with age, in each case having a larger effect (smaller or larger OR) at younger ages: rs10187424 (2p11.2, P = 0.02), rs2242652 (5p15.33, P = 0.01), rs130067 (6p21.33, P = 0.03) and rs5919432 (Xq12, P = 0.04) (Supplementary Table 4 ). This age effect has not been seen consistently for previously identified susceptibility SNPs but would be consistent with the higher familial relative risks at younger age. In addition, four SNPs showed stronger associations when we restricted the analyses to cases with a family history of PrCa: rs10187424 (2p11.2, P = 0.006), rs7584330 (2q37.2, P = 0.01), rs6763931 (3q23, P = 0.03) and rs130067 (6p21.33, P = 0.002). This is consistent with the expected enrichment of effect in familial cases under a multiplicative polygenic model (Supplementary Table 4) . A PrCa locus at 2q37.2 has recently been reported in a genome-wide linkage scan in Finnish families 8 . All of the newly associated loci lie in LD blocks that include plausible causative genes. Besides TERT, particularly notable is rs6763931 at 3q23, which lies in intron 4 of ZBTB38, which encodes a zinc finger transcriptional repressor that binds methylated DNA 9 (Fig. 2b) . The mouse homolog of ZBTB38, cibz, is a repressor of apoptosis 10 . An association between rs6763931 and human adult height has previously been reported, with the PrCa risk allele (A) being associated with increased height 11, 12 . Previous studies have suggested that tallness may be associated with an elevated risk of aggressive PrCa 13 ; researchers from a previous study 11 found that rs6763931 was the SNP most significantly correlated with ZBTB38 expression in blood and adipose tissue. rs2121875 at 5p12 is intronic in FGF10, which encodes a fibroblast growth factor essential for a range of developmental processes (Fig. 2c) . FGF10 is often overexpressed in breast carcinomas 14 , and there is some evidence to indicate a role for this gene in the growth of normal prostatic epithelial cells 15, 16 . rs130067 at 6p21 is a coding SNP (Glu>Asp) in CCHCR1 (coding for coiled-coil alpha-helical rod protein1), a gene linked with psoriasis, which is an inflammatory condition (Fig. 2d) . CCHCR1 is upregulated in skin cancer and is associated with EGFR expression 17 . CCHCR1 promotes steroidogenesis by interacting with the steroidogenic acute regulator protein (StAR) 18 and has a regulatory role in transcription factor binding 19 .
The other four associated loci are on chromosome 2p, 3q, 12q and X (Supplementary Fig. 2b-d) . rs10187424 on 2p11 is located in a generich region that includes GGCX, VAMP8, VAMP5 and RNF181, a gene encoding a DNA-damage-regulated RING finger protein. rs10936632 on 3q26 resides between the claudin gene CLDN11 and SKIL, encoding a SKI-like oncogene. rs10875943 on 12q13 is between an α-tubulin gene cluster and the peripherin gene PRPH. The X-chromosomal SNP rs5919432 is located 77 kb from AR (encoding androgen receptor).
With the identification of these new loci, more than 40 susceptibility loci for PrCa have now been identified. Most of the per-allele ORs estimated for these variants in this study population were modest, with the strongest being an OR of 0.87 associated with the minor allele of rs2242652. These results were based on imputation of common variants using the HapMap phase II reference panel and results from genotyped SNPs at stages 3 and 4. Taken together with previous GWAS analyses, these results strongly suggest that no further common variants that are imputable from the GWAS completed from l e t t e r s current genotyping platforms confer substantially higher ORs (for example, ORs greater than 1.2, as estimated for rs10993994 at MSMB, or susceptibility SNPs on 8q24). Based on an overall twofold familial relative risk to first-degree relatives of PrCa cases, and on the assumption that the SNPs combine multiplicatively, the new loci reported here together explain approximately 1.5% of the familial risk of PrCa. When previously reported loci are included, approximately 25% of familial risk in PrCa can now be explained. Under this model, the top 10% of the population at highest risk has a relative risk approximately 2.4-fold greater than the average risk in the general population, and the top 1% has an estimated 4.1-fold increased relative risk. Such risk prediction may become important for facilitating targeted screening and prevention programs. 
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